HeartWare vote for US move

By Dylan Bushell-Embling
Wednesday, 17 September, 2008

Medical device company HeartWare [ASX: HTW] has received federal court approval to go ahead with shareholder meetings to vote on its plans to redomicile in the US.

Meetings are planned for October 22.

HeartWare has appointed BDO Kendalls Corporate Finance (QLD) to independently assess the proposed scheme. BDO has determined that the scheme is in the best interest of all stockholders.

Related News

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

CTA granted for CAR-T cell therapy for multiple myeloma

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...

Content from other channels on our network

What can food manufacturers learn from viral food trends?

Cargill expands its edible oil facility in Malaysia

The mathematics of fish freshness

Mitigating unseen losses in large food packs

Perfect Automation and Omori have joined forces with packaging solutions

National Pain Alliance launched to advocate for chronic pain

Sexual misconduct findings added to public register under "landmark reforms"

Australia invests further $14.6 million in national allergy research

Can seasonal influenza vaccination prime the immune system for future strains?

"Targeted supports" launched for former patients of Simon Gordon

Leafy greens identified as potential metal mining tools

Smart monitoring helps tram network cut water use by 70%

NSW closes EV gaps in regional areas

Call for 10c increase on container return schemes

Water transition key at Global Water Summit 2026

All content Copyright © 2026 Westwick-Farrow Pty Ltd